Mylan Sulfamylon burn antimicrobial slated for advisory committee review, company says.
MYLAN SULFAMYLON BURN ANTIMICROBIAL WILL GET ADVISORY CMTE. REVIEW on July 24, Mylan VP-Investor/Public Relations Patricia Sunseri indicated during the Dillon Read generic drug/delivery systems conference in New York City May 7. FDA's Anti-Infective Drugs Advisory Committee has a tentatively scheduled meeting set for July 24-26.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth